NO175846B - - Google Patents
Download PDFInfo
- Publication number
- NO175846B NO175846B NO890565A NO890565A NO175846B NO 175846 B NO175846 B NO 175846B NO 890565 A NO890565 A NO 890565A NO 890565 A NO890565 A NO 890565A NO 175846 B NO175846 B NO 175846B
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- immunogen
- retrovirus
- virus
- infected
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 33
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims abstract description 16
- 230000002458 infectious effect Effects 0.000 claims abstract description 9
- 230000001177 retroviral effect Effects 0.000 claims abstract description 7
- 101710132601 Capsid protein Proteins 0.000 claims description 17
- 101710094648 Coat protein Proteins 0.000 claims description 17
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 17
- 101710125418 Major capsid protein Proteins 0.000 claims description 17
- 101710141454 Nucleoprotein Proteins 0.000 claims description 17
- 101710083689 Probable capsid protein Proteins 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 15
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 41
- 230000003053 immunization Effects 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 11
- 229960005486 vaccine Drugs 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 230000002480 immunoprotective effect Effects 0.000 abstract description 6
- 101710091045 Envelope protein Proteins 0.000 abstract description 5
- 101710188315 Protein X Proteins 0.000 abstract description 5
- 230000003612 virological effect Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 2
- 238000009877 rendering Methods 0.000 abstract description 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 50
- 241000700605 Viruses Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 18
- 208000030507 AIDS Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 102100034349 Integrase Human genes 0.000 description 11
- 229960000380 propiolactone Drugs 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 238000002649 immunization Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 206010001513 AIDS related complex Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 6
- 208000037357 HIV infectious disease Diseases 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000282577 Pan troglodytes Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 208000005074 Retroviridae Infections Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001466984 Simian T-lymphotropic virus 1 Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- PMOCJXSCQFTSBR-UHFFFAOYSA-N cyano(propyl)silicon Chemical compound CCC[Si]C#N PMOCJXSCQFTSBR-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6028087A | 1987-06-10 | 1987-06-10 | |
| US20075288A | 1988-05-31 | 1988-05-31 | |
| PCT/US1988/001955 WO1988009670A1 (fr) | 1987-06-10 | 1988-06-09 | Prevention et traitement de maladies retrovirales |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO890565L NO890565L (no) | 1989-02-09 |
| NO890565D0 NO890565D0 (no) | 1989-02-09 |
| NO175846B true NO175846B (fr) | 1994-09-12 |
| NO175846C NO175846C (no) | 1994-12-21 |
Family
ID=26739775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO890565A NO175846C (no) | 1987-06-10 | 1989-02-09 | Fremgangsmåte for å oppnå et immunogen |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP0602761A1 (fr) |
| JP (1) | JPH0720880B2 (fr) |
| AT (1) | ATE132374T1 (fr) |
| AU (1) | AU612383B2 (fr) |
| CA (1) | CA1336407C (fr) |
| DE (1) | DE3854857T2 (fr) |
| DK (1) | DK56389A (fr) |
| FI (1) | FI95871C (fr) |
| IL (1) | IL86675A (fr) |
| NO (1) | NO175846C (fr) |
| OA (1) | OA09037A (fr) |
| RU (1) | RU2111010C1 (fr) |
| UA (1) | UA27716C2 (fr) |
| WO (1) | WO1988009670A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ223980A (en) * | 1987-03-23 | 1991-02-26 | Hiver Ltd | An aids-type virus vaccine comprising an antibody equivalent which recognises an epitope on a cd4 cell-marker |
| US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| US5227159A (en) * | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
| EP0474868B1 (fr) * | 1989-05-30 | 1996-11-13 | Nippon Zeon Co., Ltd. | Procede de production de structures de noyau de retrovirus et particules ainsi produites |
| FR2661834B1 (fr) * | 1990-05-09 | 1995-01-27 | Merieux Inst | Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus. |
| WO1994002171A1 (fr) * | 1992-07-20 | 1994-02-03 | The Immune Response Corporation | Methode prophylactique et therapeutique de lutte contre les infections retrovirales |
| DK0751988T3 (da) * | 1994-03-22 | 2000-06-26 | Immune Response Corp Inc | Højeffektiv fremstilling og isolering af virale partikler |
| IT1271593B (it) * | 1994-11-30 | 1997-06-04 | Sanitaria Scaligera Spa | Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716102A (en) * | 1984-08-15 | 1987-12-29 | Regents Of The University Of California | Purified AIDS-associated virus ARV-2 |
| DK507185A (da) * | 1984-11-05 | 1986-05-06 | Du Pont | Fremgangsmaade til inaktivering af human tumor leukaemi virus iii |
| US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
| DE3588134T2 (de) * | 1984-12-24 | 1997-03-20 | Genentech Inc | Fusionen von AIDS-verwandten Polypeptiden |
| ES8706824A1 (es) * | 1985-04-08 | 1987-07-01 | Genetic Systems Corp | Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia. |
| DK171119B1 (da) * | 1985-04-19 | 1996-06-17 | Hoffmann La Roche | AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin |
| EP0249611A4 (fr) * | 1985-11-14 | 1988-04-26 | Harvard College | Virus t-lymphotrophique. |
| EP0250128A3 (fr) * | 1986-06-18 | 1988-06-08 | American Registry of Pathology | Virus isolé de patients atteints du SIDA |
| WO1988007058A1 (fr) * | 1987-03-16 | 1988-09-22 | Biosolutions Pty. Ltd. | Anticorps antiparatopique servant d'immunogene |
-
1988
- 1988-06-09 AT AT88906347T patent/ATE132374T1/de not_active IP Right Cessation
- 1988-06-09 AU AU19626/88A patent/AU612383B2/en not_active Ceased
- 1988-06-09 EP EP93250368A patent/EP0602761A1/fr not_active Withdrawn
- 1988-06-09 RU SU5052305A patent/RU2111010C1/ru not_active IP Right Cessation
- 1988-06-09 WO PCT/US1988/001955 patent/WO1988009670A1/fr active IP Right Grant
- 1988-06-09 JP JP63505484A patent/JPH0720880B2/ja not_active Expired - Fee Related
- 1988-06-09 CA CA000569026A patent/CA1336407C/fr not_active Expired - Fee Related
- 1988-06-09 DE DE3854857T patent/DE3854857T2/de not_active Expired - Fee Related
- 1988-06-09 IL IL86675A patent/IL86675A/xx not_active IP Right Cessation
- 1988-06-09 EP EP95250152A patent/EP0685236A1/fr not_active Withdrawn
- 1988-06-09 UA UA5052305A patent/UA27716C2/uk unknown
- 1988-06-09 EP EP88906347A patent/EP0317622B1/fr not_active Expired - Lifetime
-
1989
- 1989-02-08 FI FI890603A patent/FI95871C/fi not_active IP Right Cessation
- 1989-02-08 DK DK056389A patent/DK56389A/da not_active Application Discontinuation
- 1989-02-09 NO NO890565A patent/NO175846C/no unknown
- 1989-02-10 OA OA59525A patent/OA09037A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0720880B2 (ja) | 1995-03-08 |
| FI95871C (fi) | 1996-04-10 |
| EP0602761A1 (fr) | 1994-06-22 |
| FI890603A0 (fi) | 1989-02-08 |
| DE3854857T2 (de) | 1996-08-22 |
| UA27716C2 (uk) | 2000-10-16 |
| NO890565L (no) | 1989-02-09 |
| NO890565D0 (no) | 1989-02-09 |
| ATE132374T1 (de) | 1996-01-15 |
| NO175846C (no) | 1994-12-21 |
| DE3854857D1 (de) | 1996-02-15 |
| EP0317622B1 (fr) | 1996-01-03 |
| WO1988009670A1 (fr) | 1988-12-15 |
| JPH02500440A (ja) | 1990-02-15 |
| RU2111010C1 (ru) | 1998-05-20 |
| CA1336407C (fr) | 1995-07-25 |
| FI890603A (fi) | 1989-02-08 |
| AU612383B2 (en) | 1991-07-11 |
| EP0317622A4 (fr) | 1990-05-14 |
| AU1962688A (en) | 1989-01-04 |
| EP0685236A1 (fr) | 1995-12-06 |
| EP0317622A1 (fr) | 1989-05-31 |
| DK56389D0 (da) | 1989-02-08 |
| IL86675A (en) | 1993-04-04 |
| FI95871B (fi) | 1995-12-29 |
| DK56389A (da) | 1989-02-08 |
| OA09037A (en) | 1991-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5885578A (en) | Prevention and treatment of retroviral disease | |
| Earl et al. | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses | |
| Wang et al. | Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant | |
| Barin et al. | Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa | |
| Montefiori et al. | Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection | |
| Girard et al. | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 | |
| Luo et al. | Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells | |
| EP0345375A1 (fr) | Rétrovirus HIV-3 et son utilisation | |
| PUTKONEN et al. | Vaccine protection against HIV-2 infection in cynomolgus monkeys | |
| US5861282A (en) | Non-infectious HIV particles and uses therefor | |
| Lockridge et al. | Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA | |
| De Rossi et al. | Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism | |
| NO175846B (fr) | ||
| MULLIGAN et al. | The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation | |
| US5876724A (en) | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
| Hosie | The development of a vaccine against feline immunodeficiency virus | |
| US9879230B2 (en) | Chimeric non-integrating lentiviral genomes as vaccines against HIV-1 | |
| IL104337A (en) | Antibodies that react with one or more retroviral VIH proteins | |
| MARCUS-SEKURA et al. | Epitope mapping of the HIV-1 gag region by analysis of gag gene deletion fragments expressed in Escherichia coli defines eight antigenic determinants | |
| Pancino et al. | Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope | |
| RU1837890C (ru) | Способ получени иммуногена, стимулирующего иммунную систему человека, зараженного HIY | |
| Pinto et al. | T‐helper reactivity to simian immunodeficiency virus gag synthetic peptides in human immunodeficiency virus type 2 infected individuals | |
| Bukrinsky et al. | False‐positive sera do not react with human immunodeficiency virus (HIV) Gag‐encoded recombinant antigen | |
| Krohn et al. | Proliferative T‐Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings | |
| Monti | An evolutionary approach to vaccine strain selection: Ancestral and consensus HIV-1 envelope immunogens |